80,000 Shares in Biohaven Pharmaceutical Holding Co Ltd (BHVN) Purchased by Candriam Luxembourg S.C.A.

Candriam Luxembourg S.C.A. bought a new stake in Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) in the fourth quarter, HoldingsChannel.com reports. The institutional investor bought 80,000 shares of the company’s stock, valued at approximately $2,158,000.

Other institutional investors have also added to or reduced their stakes in the company. Deschutes Portfolio Strategy LLC purchased a new position in shares of Biohaven Pharmaceutical in the third quarter valued at $374,000. Strs Ohio purchased a new position in shares of Biohaven Pharmaceutical in the third quarter valued at $680,000. Nationwide Fund Advisors purchased a new position in shares of Biohaven Pharmaceutical in the third quarter valued at $214,000. Emerald Advisers Inc. PA purchased a new position in shares of Biohaven Pharmaceutical in the third quarter valued at $9,096,000. Finally, Emerald Mutual Fund Advisers Trust purchased a new position in shares of Biohaven Pharmaceutical in the third quarter valued at $7,483,000. 52.82% of the stock is owned by institutional investors.

Shares of Biohaven Pharmaceutical Holding Co Ltd (NYSE BHVN) opened at $29.61 on Tuesday. Biohaven Pharmaceutical Holding Co Ltd has a 52-week low of $17.00 and a 52-week high of $39.51.

A number of brokerages have recently weighed in on BHVN. Zacks Investment Research cut Biohaven Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Tuesday, January 30th. Canaccord Genuity began coverage on Biohaven Pharmaceutical in a research report on Friday, December 15th. They issued a “buy” rating and a $30.00 price target for the company. BidaskClub cut Biohaven Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Friday, October 27th. Piper Jaffray Companies set a $48.00 price target on Biohaven Pharmaceutical and gave the company a “buy” rating in a research report on Monday, December 11th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $36.00 price objective on shares of Biohaven Pharmaceutical in a research report on Wednesday, November 15th. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company. Biohaven Pharmaceutical presently has a consensus rating of “Buy” and an average price target of $36.14.

In other Biohaven Pharmaceutical news, Director Declan Doogan sold 128,058 shares of Biohaven Pharmaceutical stock in a transaction dated Thursday, January 18th. The stock was sold at an average price of $26.95, for a total value of $3,451,163.10. Following the completion of the sale, the director now owns 2,583,289 shares in the company, valued at approximately $69,619,638.55. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Gregory Bailey sold 50,000 shares of Biohaven Pharmaceutical stock in a transaction dated Wednesday, January 31st. The shares were sold at an average price of $33.71, for a total value of $1,685,500.00. Following the completion of the sale, the director now owns 2,516,701 shares of the company’s stock, valued at approximately $84,837,990.71. The disclosure for this sale can be found here. In the last quarter, insiders have sold 858,608 shares of company stock valued at $24,218,849.

WARNING: This report was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another domain, it was illegally copied and reposted in violation of US & international trademark & copyright legislation. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2018/02/20/80000-shares-in-biohaven-pharmaceutical-holding-co-ltd-bhvn-purchased-by-candriam-luxembourg-s-c-a.html.

Biohaven Pharmaceutical Company Profile

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Want to see what other hedge funds are holding BHVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN).

Institutional Ownership by Quarter for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply